GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization’s ...

Shares of GeoVax Labs Inc. ($GOVX), SIGA Technologies Inc. ($SIGA), and Emergent Biosolutions Inc. ($EBS) gained in mid-day trading on Friday after the World Health ...

GeoVax Labs Inc (NASDAQ:GOVX) shares are trading lower Tuesday, pulling back from recent strength after the company announced an offering of 1.7 million shares at a price of $5 per share.

Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology ...

10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA's Clinical Studies ...

GeoVax Labs Inc.’s stock soared 43% Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet i ...

GeoVax’s product pipeline includes three ongoing clinical trials for which the funding will largely be used. How Atlanta took a leading role in Covid-19 vaccine research Atlanta, Chinese ...

The $20 million will be used to accelerate three ongoing clinical trials by the company for Covid-19 vaccines and cancer treatments. In January, GeoVax raised $10 million for the same clinical trials.

ATLANTA, GA - June 11, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a ...